Portal de Periódicos da CAPES

Tissue Inhibitor of Metalloproteinases-3 Promoter Methylation is an Independent Prognostic Factor for Bladder Cancer

2007; Lippincott Williams & Wilkins; Volume: 179; Issue: 2 Linguagem: Inglês

10.1016/j.juro.2007.09.019

1527-3792

Mohammad Obaidul Hoque, Shahnaz Begum, Mariana Brait, Cármen Jerónimo, Marianna Zahurak, Kimberly Laskie Ostrow, Eli Rosenbaum, Bruce J. Trock, William H. Westra, Mark Schoenberg, Steven N. Goodman, David Sidransky,

Ferroptosis and cancer prognosis

No AccessJournal of UrologyInvestigative urology1 Feb 2008Tissue Inhibitor of Metalloproteinases-3 Promoter Methylation is an Independent Prognostic Factor for Bladder Canceris companion ofRole of Urinary Cathepsin B and L in the Detection of Bladder Urothelial Cell CarcinomaPrevention of Recurrence With Epirubicin and Lactobacillus Casei After Transurethral Resection of Bladder Cancer Mohammad Obaidul Hoque, Shahnaz Begum, Mariana Brait, Carmen Jeronimo, Marianna Zahurak, Kimberly Laskie Ostrow, Eli Rosenbaum, Bruce Trock, William H. Westra, Mark Schoenberg, Steven N. Goodman, and David Sidransky Mohammad Obaidul HoqueMohammad Obaidul Hoque Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland , Shahnaz BegumShahnaz Begum Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland , Mariana BraitMariana Brait Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland , Carmen JeronimoCarmen Jeronimo Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland , Marianna ZahurakMarianna Zahurak Department of Biostatistics/Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland , Kimberly Laskie OstrowKimberly Laskie Ostrow Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland , Eli RosenbaumEli Rosenbaum Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland , Bruce TrockBruce Trock The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland , William H. WestraWilliam H. Westra Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland , Mark SchoenbergMark Schoenberg The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland , Steven N. GoodmanSteven N. Goodman Department of Biostatistics/Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland , and David SidranskyDavid Sidransky Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland View All Author Informationhttps://doi.org/10.1016/j.juro.2007.09.019AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: TIMP-3 (tissue inhibitor of metalloproteinases-3) is 1 of 4 members of a family of proteins that were originally classified according to their ability to inhibit matrix metalloproteinases. We analyzed TIMP-3 methylation in 175 urine sediment DNA samples from patients with bladder cancer with well characterized clinicopathological parameters, including patient outcome. Materials and Methods: We examined urine sediment DNA for aberrant methylation of 9 genes, including TIMP-3, by quantitative fluorogenic real-time polymerase chain reaction. Results: Using an optimal cutoff value by TaqMan® quantitation we found that the risk of death was statistically significantly higher in patients with higher TIMP-3 and ARF methylation (HR 1.99, 95% CI 1.12 to 3.27, p = 0.01 and HR 1.66, 95% CI 1.00 to 2.76, p = 0.05, respectively) than in patients without/lower TIMP3 and ARF methylation in urine. A significant correlation was also seen between the risk of death and stage 3 tumor (HR 2.73, 95% CI 1.58 to 4.72, p = 0.003) and metastasis (HR 3.32, 95% CI 1.98 to 5.57, p = 0.0001). Multivariate analysis subsequently revealed that TIMP-3 methylation was an independent prognostic factor for bladder cancer survival with stage and metastasis (p = 0.001 and 0.02, respectively). Conclusions: These results suggest that TIMP-3 promoter methylation could be a clinically applicable marker for bladder cancer progression. References 1 : Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol2001; 19: 666. Crossref, Medline, Google Scholar 2 : Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol1998; 160: 645. Link, Google Scholar 3 : Emerging molecular markers of cancer. Nat Rev Cancer2002; 2: 210. Google Scholar 4 : DNA methylation and cancer. Oncogene2002; 21: 5358. Google Scholar 5 : Human TIMP-3 is expressed during fetal development, hair growth cycle, and cancer progression. J Histochem Cytochem1998; 46: 437. Google Scholar 6 : Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res1998; 58: 2310. Google Scholar 7 : Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis1996; 17: 1805. Google Scholar 8 : TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Br J Cancer1997; 75: 1678. Google Scholar 9 : Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res2003; 63: 2216. Google Scholar 10 : Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A1996; 93: 9821. Google Scholar 11 : Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res2003; 9: 1370. Google Scholar 12 : Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst2006; 98: 996. Google Scholar 13 : High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Res2003; 63: 5723. Google Scholar 14 : Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res2003; 9: 2912. Google Scholar 15 : PUMA in head and neck cancer. Cancer Lett2003; 199: 75. Google Scholar 16 : Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med2003; 349: 859. Google Scholar 17 : Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol2004; 202: 395. Google Scholar 18 : Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res1999; 59: 798. Google Scholar 19 : TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem2000; 275: 31226. Google Scholar 20 : A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med2003; 9: 407. Google Scholar © 2008 by American Urological AssociationFiguresReferencesRelatedDetailsCited byGarcía-Baquero R, Puerta P, Beltran M, Alvarez M, Sacristan R, Alvarez-Ossorio J and Sánchez-Carbayo M (2018) Methylation of a Novel Panel of Tumor Suppressor Genes in Urine Moves Forward Noninvasive Diagnosis and Prognosis of Bladder Cancer: A 2-Center Prospective StudyJournal of Urology, VOL. 190, NO. 2, (723-730), Online publication date: 1-Aug-2013.Related articlesJournal of Urology12 Dec 2007Role of Urinary Cathepsin B and L in the Detection of Bladder Urothelial Cell CarcinomaJournal of Urology12 Dec 2007Prevention of Recurrence With Epirubicin and Lactobacillus Casei After Transurethral Resection of Bladder Cancer Volume 179Issue 2February 2008Page: 743-747 Advertisement Copyright & Permissions© 2008 by American Urological AssociationKeywordstissue inhibitor of metalloproteinase-3bladder neoplasmsbladdermethylationbiologicaltumor markersMetricsAuthor Information Mohammad Obaidul Hoque Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland Financial interest and/or other relationship with GlaxoSmithKline, Elsevier, Teng, Viventia and Pfizer. More articles by this author Shahnaz Begum Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland More articles by this author Mariana Brait Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Carmen Jeronimo Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Marianna Zahurak Department of Biostatistics/Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Kimberly Laskie Ostrow Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Eli Rosenbaum Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Bruce Trock The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland More articles by this author William H. Westra Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland More articles by this author Mark Schoenberg The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland More articles by this author Steven N. Goodman Department of Biostatistics/Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author David Sidransky Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland Financial interest and/or other relationship with Oncomethylome Sciences. More articles by this author Expand All Advertisement PDF downloadLoading ...